×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

Brookline Capital Management Analyst Recommendations & Stock Picks

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Brookline Capital Management. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Brookline Capital Management.

MarketRank evaluates a company based on community opinion, dividend strength, institutional and insider ownership, earnings and valuation, and analysts forecasts.
Available with a MarketBeat All Access Subscription
MarketRank™Upgrade to All Access to use the All Ranks Filter
Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.
Available with a MarketBeat All Access Subscription
Media SentimentUpgrade to All Access to use the All Sentiments Filter
Analyst consensus is the average investment recommendation among Wall Street research analysts.
Available with a MarketBeat All Access Subscription
Analyst ConsensusUpgrade to All Access to use the All Ratings Filter
CompanyDateActionBrokerageAnalystRatingPrice TargetImpact on PriceDetailsActions
VERU
Veru
5/18/2022Target Raised byBrookline Capital ManagementAnalyst Kumaraguru RajaBuy -> Buy$29.00 -> $31.00Medium
VRCA
Verrica Pharmaceuticals
3/10/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyMedium
NTLA
Intellia Therapeutics
3/7/2022Upgraded byBrookline Capital ManagementAnalyst L. CannHold -> Buy $91.00High
CTIC
CTI BioPharma
3/1/2022Target Raised byBrookline Capital ManagementAnalyst L. CannBuy -> Buy$7.20 -> $12.00High
CRSP
CRISPR Therapeutics
2/14/2022Reiterated byBrookline Capital ManagementAnalyst Leah RushBuy $143.00High
NTLA
Intellia Therapeutics
2/14/2022Reiterated byBrookline Capital ManagementAnalyst Leah RushBuyLow
CRBU
Caribou Biosciences
2/14/2022Reiterated byBrookline Capital ManagementAnalyst L. CannBuyMedium
BCDA
BioCardia
2/3/2022Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyHigh
FUSN
Fusion Pharmaceuticals
2/2/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyMedium
HEPA
Hepion Pharmaceuticals
1/26/2022Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow
DARE
Daré Bioscience
1/19/2022Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyHigh
PROC
Procaps Group
12/14/2021Reiterated byBrookline Capital ManagementAnalyst Kemp DolliverBuy $13.00Low
PNT
POINT Biopharma Global
12/1/2021Reiterated byBrookline Capital ManagementAnalyst Kemp DolliverBuy $23.00Medium
CTIC
CTI BioPharma
11/15/2021Reiterated byBrookline Capital ManagementAnalyst L. CannBuyHigh
NOVN
Novan
10/19/2021Reiterated byBrookline Capital ManagementAnalyst Kemp DolliverBuy $16.00Medium
ADIL
Adial Pharmaceuticals
10/13/2021Reiterated byBrookline Capital ManagementAnalyst Kumaraguru RajaBuy $12.00High
KYMR
Kymera Therapeutics
10/13/2021Reiterated byBrookline Capital ManagementAnalyst Leah Rush CannBuy $80.00Medium
BIOC
Biocept
10/8/2021Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyMedium
FBRX
Forte Biosciences
9/3/2021Reiterated byBrookline Capital ManagementAnalyst K. RajaHoldLow
VERU
Veru
8/27/2021Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyMedium
SCYX
SCYNEXIS
8/24/2021Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow
CLSN
Celsion
8/12/2021Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyMedium
BCEL
Atreca
7/29/2021Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyHigh
CCCC
C4 Therapeutics
6/25/2021Reiterated byBrookline Capital ManagementAnalyst Leah Rush CannBuyHigh
CLBS
Caladrius Biosciences
6/22/2021Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow
ATE
Antibe Therapeutics
6/3/2021Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyN/A
ATBPF
Antibe Therapeutics
6/3/2021Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyMedium
MNPR
Monopar Therapeutics
5/25/2021Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyMedium
BIOX
Bioceres Crop Solutions
5/7/2021Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyN/A
SQZ
SQZ Biotechnologies
3/30/2021Reiterated byBrookline Capital ManagementAnalyst L. CannBuyN/A
ONCT
Oncternal Therapeutics
3/30/2021Reiterated byBrookline Capital ManagementAnalyst K. RajaBuy $16.00High
NMTR
9 Meters Biopharma
3/25/2021Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyHigh
CLBS
Caladrius Biosciences
3/3/2021Target Raised byBrookline Capital ManagementBuy$7.00 -> $10.00High
MRNA
Moderna
2/26/2021Target Raised byBrookline Capital ManagementBuy$180.00 -> $205.00Low
CNSP
CNS Pharmaceuticals
2/2/2021Initiated byBrookline Capital ManagementAnalyst K. RajaBuy $10.00Low
XFOR
X4 Pharmaceuticals
12/17/2020Initiated byBrookline Capital ManagementAnalyst L. CannBuy $21.00High
VERU
Veru
12/14/2020Target Raised byBrookline Capital ManagementAnalyst K. Raja$13.00 -> $17.00High
SYRS
Syros Pharmaceuticals
11/10/2020Initiated byBrookline Capital ManagementAnalyst L. CannBuy $19.00Low
CTIC
CTI BioPharma
10/23/2020Initiated byBrookline Capital ManagementAnalyst L. CannBuy $7.00Medium
ECOR
electroCore
10/23/2020Initiated byBrookline Capital ManagementAnalyst S. YanchusBuy $5.00Low
AWH
Aspira Women's Health
10/14/2020Reiterated byBrookline Capital ManagementAnalyst S. YanchusBuyHigh
MEIP
MEI Pharma
10/12/2020Reiterated byBrookline Capital ManagementAnalyst L. CannBuyMedium
DMTK
DermTech
9/11/2020Initiated byBrookline Capital ManagementAnalyst S. YanchusBuyHigh
MDNA
Medicenna Therapeutics
8/24/2020Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyMedium
FBRX
Forte Biosciences
8/28/2020Initiated byBrookline Capital ManagementAnalyst K. RajaBuy $90.00Low
HUGE
FSD Pharma
8/20/2020Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow
HUGE
FSD Pharma
8/20/2020Initiated byBrookline Capital ManagementBuy $11.00N/A
KURA
Kura Oncology
8/16/2020Reiterated byBrookline Capital ManagementAnalyst L. CannBuyLow
NMTR
9 Meters Biopharma
8/18/2020Initiated byBrookline Capital ManagementAnalyst S. YanchusBuy $5.00High
VERU
Veru
8/14/2020Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow
ARCT
Arcturus Therapeutics
8/11/2020Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow
ATE
Antibe Therapeutics
7/15/2020Reiterated byBrookline Capital ManagementAnalyst S. YanchusBuyN/A
MRNA
Moderna
7/13/2020Reiterated byBrookline Capital ManagementAnalyst L. CannBuy $95.00High
ASRT
Assertio
6/3/2020Initiated byBrookline Capital ManagementBuy $3.50Low
CWBR
CohBar
5/27/2020Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyMedium
CWBR
CohBar
5/28/2020Initiated byBrookline Capital ManagementBuyN/A
CLBS
Caladrius Biosciences
5/25/2020Initiated byBrookline Capital ManagementAnalyst K. RajaBuy $7.00High
CYCC
Cyclacel Pharmaceuticals
5/19/2020Initiated byBrookline Capital ManagementAnalyst K. RajaBuy $22.00High
BIOC
Biocept
5/14/2020Initiated byBrookline Capital ManagementAnalyst S. YanchusBuyHigh
OTLK
Outlook Therapeutics
5/5/2020Initiated byBrookline Capital ManagementAnalyst K. RajaBuyHigh
DARE
Daré Bioscience
4/28/2020Initiated byBrookline Capital ManagementAnalyst S. YanchusBuy $7.50High
EDSA
Edesa Biotech
3/30/2020Initiated byBrookline Capital ManagementAnalyst K. RajaBuy $10.00High
CLPT
ClearPoint Neuro
3/11/2020Reiterated byBrookline Capital ManagementAnalyst S. YanchusBuyHigh
ARMP
Armata Pharmaceuticals
3/13/2020Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyHigh
CLPT
ClearPoint Neuro
3/12/2020Initiated byBrookline Capital ManagementBuy $15.00N/A
MNPR
Monopar Therapeutics
2/19/2020Initiated byBrookline Capital ManagementAnalyst K. RajaBuy $42.00High
BIOX
Bioceres Crop Solutions
2/4/2020Reiterated byBrookline Capital ManagementAnalyst S. YanchusBuyN/A
BCDA
BioCardia
11/26/2019Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow
BCDA
BioCardia
11/26/2019Initiated byBrookline Capital ManagementBuy $22.00Low
MDNA
Medicenna Therapeutics
11/19/2019Reiterated byBrookline Capital ManagementBuy C$4.00N/A
BCEL
Atreca
8/20/2019Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyHigh
SCYX
SCYNEXIS
8/19/2019Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyHigh
VXRT
Vaxart
8/15/2019Initiated byBrookline Capital ManagementAnalyst K. RajaBuy $6.00Low
CLSN
Celsion
7/25/2019Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyMedium
VERU
Veru
7/29/2019Initiated byBrookline Capital ManagementAnalyst K. RajaBuy $12.00High
NHWK
NightHawk Biosciences
7/29/2019Initiated byBrookline Capital ManagementAnalyst K. RajaBuy$56.00 -> $56.00High
CLRB
Cellectar Biosciences
7/29/2019Initiated byBrookline Capital ManagementAnalyst K. RajaBuy$6.00 -> $6.00High
ARCT
Arcturus Therapeutics
7/24/2019Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyHigh
SCYX
SCYNEXIS
1/4/2019Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyHigh
CLSN
Celsion
11/20/2018Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyMedium
CLRB
Cellectar Biosciences
11/20/2018Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow
ARCT
Arcturus Therapeutics
9/27/2018Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow
NHWK
NightHawk Biosciences
8/1/2018Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow
TNXP
Tonix Pharmaceuticals
7/27/2018Downgraded byBrookline Capital ManagementAnalyst K. RajaBuy -> HoldLow
TNXP
Tonix Pharmaceuticals
5/1/2018Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLow

MarketBeat Community Rating for Brookline Capital Management

Community Ranking:  3.0 out of 5 (
3 of 5 stars)
Outperform Votes:  17,755 (Vote Outperform)
Underperform Votes:  12,310 (Vote Underperform)
Total Votes:  30,065
MarketBeat's community ratings are surveys of what our community members think about Brookline Capital Management and other research firms. Vote "Outperform" if you believe Brookline Capital Management's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Brookline Capital Management's recommendations will underperform the S&P 500 over the long term. You may vote once every thirty days.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.